Premium
Cytoreductive nephrectomy in the era of targeted therapies: a review
Author(s) -
Pindoria Nisha,
Raison Nicholas,
Blecher Gideon,
Catterwell Rick,
Dasgupta Prokar
Publication year - 2017
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.13860
Subject(s) - medicine , immunotherapy , renal cell carcinoma , nephrectomy , targeted therapy , oncology , clinical trial , systemic therapy , surgery , cancer , kidney , breast cancer
In the pre‐targeted therapy era, palliative cytoreductive nephrectomy combined with cytokine immunotherapy was the standard treatment protocol for the management of metastatic renal cell carcinoma. The introduction of targeted therapies has improved response rates, median survival and overall prognosis when compared to immunotherapy. The role of cytoreductive nephrectomy in providing an independent survival advantage when used alongside immunotherapy has been demonstrated by two randomised controlled trials. However, with the new shift in improved treatment outcomes from cytokine immunotherapy to targeted therapies, the continuing role of cytoreductive nephrectomy as a viable surgical treatment method remains controversial.